Maxwell Lloyd, MD

Articles by Maxwell Lloyd, MD

Dr Lloyd on the Potential Role for T-DXd in Early-Stage HER2+ Breast Cancer

January 22nd 2026

Maxwell Lloyd, MD, discusses phase 3 data from DESTINY-Breast11 and DESTINY-Breast05 evaluating T-DXd in neoadjuvant and adjuvant HER2-positive breast cancer.

Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer

ByMaxwell Lloyd, MD

December 13th 2024

Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

Oncology Fellows Presents a New Drug Cheat Sheet for Fellows

Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC

Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant